URMC to initiate clinical trials to test HCQ in COVID-19 treatment
Category: #health  By Saipriya Iyer  Date: 2020-06-04
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

URMC to initiate clinical trials to test HCQ in COVID-19 treatment

URMC researchers are going to join a couple of new national clinical trials in the coming week to be able to test if hydroxychloroquine (HCQ), which is essentially an anti-malarial drug approved by the FDA, will be able to keep the patients suffering from COVID-19 alive and later out of the hospital. HCQ has been recognized as the most potent treatment medicine for coronavirus, but the research studies on coronavirus have reported results that are inconclusive and contradictory so far.

The trials are more controlled and randomized, separately sponsored by the Novartis pharmaceutical firm and the National Institute of Allergy and Infectious disease. These trials are designed in a way to offer clear and conclusive evidence that will be able to direct the future treatment of patients suffering from COVID-19.

Certain patients shall be treated with the anti-malarial drug both with and even without the antibiotic azithromycin that is usually used to treat problems of respiratory infections whereas others shall receive a placebo.

University of Rochester Medical Center Professor and Chief of Infectious Disease, as well as the local leader of the studies, Michael Keefer, MD., said that it is not yet known if the drug, HCQ, will be able to help patients recover from coronavirus disease which is why is crucial for everyone to do a careful study in a very controlled manner. The researchers are hopeful that the treatment is effective, however, it wouldn’t be shown until a study of this kind shall be done.

As per Keefer, hydroxychloroquine being a pill that can be taken, has made it especially attractive for the treatment of non-hospitalized patients. Remdesivir is the only drug that has been cleared for the treatment of COVID-19 and is given out after intravenous infusion which mostly makes it a good choice for all the patients hospitalized but can be less convenient for the outpatients.

 

Source Credit- https://www.urmc.rochester.edu/news/story/5660/urmc-launches-clinical-trials-to-test-hydroxychloroquine-in-covid-19-patients.aspx



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...